Expertise in
62
conditions

Dr. Donald P. Quick

Hematology Oncology | Oncology
4101 22nd Place, 
Lubbock, TX 
Accepting New Patients
44 Years of Experience
Referral may be required
Expertise in
62
conditions
4101 22nd Place, 
Lubbock, TX 

Overview

Donald Quick is a Hematologist Oncology specialist and an Oncologist practicing medicine in Lubbock, Texas. He has been practicing medicine for over 44 years.

Dr. Quick is highly rated in 62 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 16 peer reviewed articles and participating in 9 clinical trials. Dr. Quick is currently accepting new patients.

Graduate Year

1982

Specialties

Hematology Oncology
Oncology

Licenses

Internal Medicine in NM

Hospital Affiliations

Covenant Hospital Plainview
Nor-Lea Hospital District
Artesia General Hospital
Covenant Medical Center
Covenant Childrens Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
FirstCare
  • HMO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Scott and White Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Sky Community Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER COMMERCIAL
View 13 Less Insurance Carriers -

Locations

4101 22nd Place, Lubbock, TX 79410

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Enrollment Status: Active_not_recruiting
Publish Date: March 09, 2026
Intervention Type: Drug
Study Drugs: Zanubrutinib, Bendamustine, Rituximab, Venetoclax
Study Phase: Phase 3
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Other, Drug
Study Drug: Lenalidomide
Study Phase: Phase 3
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Enrollment Status: Completed
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: Pevonedistat, Venetoclax, Azacitidine
Study Phase: Phase 2
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
Phase 1 Trial of Dose Escalated BGB324 in Combination With Docetaxel for Previously Treated Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 1 Trial of Dose Escalated BGB324 in Combination With Docetaxel for Previously Treated Advanced Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: February 21, 2024
Intervention Type: Drug
Study Drugs: BGB324, Docetaxel
Study Phase: Phase 1
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1 Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Durvalumab in Patients With Advanced Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
A Phase 1 Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Durvalumab in Patients With Advanced Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
Enrollment Status: Terminated
Publish Date: October 26, 2021
Intervention Type: Drug
Study Phase: Phase 1
Phase I/II Trial of Fenretinide/LXS Oral Powder (NSC 374551) Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma
Phase I/II Trial of Fenretinide/LXS Oral Powder (NSC 374551) Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma
Enrollment Status: Terminated
Publish Date: August 27, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b
An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b
Enrollment Status: Terminated
Publish Date: March 11, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

16 Total Publications

Pembrolizumab Induced Recall Dermatitis Occurring 5 Years After Radiotherapy.
Pembrolizumab Induced Recall Dermatitis Occurring 5 Years After Radiotherapy.
Journal: Reports (MDPI)
Published: May 23, 2024
Similar Doctors
Expertise in
39
conditions
Dr. Isaac Tafur
Hematology Oncology | Oncology
Expertise in
39
conditions
Dr. Isaac Tafur
Hematology Oncology | Oncology
4101 22nd Place, 
Lubbock, TX 
 (0.2 miles away)
806-725-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Isaac Tafur is a Hematologist Oncology specialist and an Oncologist practicing medicine in Lubbock, Texas. Dr. Tafur is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Inflammatory Breast Cancer, Lung Cancer, Paget Disease of the Breast, and Small Cell Lung Cancer (SCLC). Dr. Tafur is currently accepting new patients.

Expertise in
13
conditions
Dr. Thomas Hutson
Oncology
Expertise in
13
conditions
Dr. Thomas Hutson
Oncology

UMC Cancer Center

602 Indiana Ave, 
Lubbock, TX 
 (1.3 miles away)
806-775-8600
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Hutson is an Oncologist practicing medicine in Lubbock, Texas. Dr. Hutson is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, WT1-Related Wilms Tumor Syndromes, Nephrectomy, and Orchiectomy.

Expertise in
42
conditions
Dr. Rodolfo E. Martinez
Oncology | Hematology Oncology
Expertise in
42
conditions
Dr. Rodolfo E. Martinez
Oncology | Hematology Oncology
4101 22nd Place, 
Lubbock, TX 
 (0.2 miles away)
806-725-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rodolfo Martinez is a Hematologist Oncology specialist and an Oncologist practicing medicine in Lubbock, Texas. Dr. Martinez is highly rated in 42 conditions, according to our data. His clinical expertise encompasses Inflammatory Breast Cancer, Paget Disease of the Breast, Breast Cancer, Angiosarcoma, and Bone Marrow Aspiration. Dr. Martinez is currently accepting new patients.

Frequently Asked Questions about Dr. Donald P. Quick

How do I make an appointment with Dr. Donald P. Quick?

You can book an appointment with Dr. Donald P. Quick by calling their office at 806-725-8000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Donald P. Quick a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Donald P. Quick is classified as an Distinguished expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Donald P. Quick specialize in?

While Dr. Donald P. Quick is a Hematology Oncology, they have specific expertise in Non-Hodgkin Lymphoma, Immune Thrombocytopenic Purpura (ITP), and Adult Immune Thrombocytopenia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Donald P. Quick participate in research or clinical trials?

Yes. Dr. Donald P. Quick has published 16 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Donald P. Quick's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Donald P. Quick accept my insurance?

Dr. Donald P. Quick accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 806-725-8000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Quick's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 51 Advanced Conditions
    View All 121 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile